Phase 2 N=27 A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
Severe Sepsis With Septic Shock
Primary: Immune Reconstitution of Lymphocytopenic Sepsis Patients — 8; 7; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=135 A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 16.2; 31.3 percentage of participants — p=0.0310
Phase 2 N=43 RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor
Primary: Response Rate — 16 Participants
Phase 2 N=131 Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
Venous Thromboembolism · Deep Venous Thrombosis · Surgery
Primary: Number of Patients With in Range Initial Peak Xa Level — 27; 27 Participants
Phase 2 N=50 Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
Lymphoma
Primary: Mobilization Rate — 50 Participants
Phase 2 N=30 Botulinum Toxin for Pelvic Pain in Women With Endometriosis
Endometriosis · Chronic Pelvic Pain · Pelvic Muscle Spasm
Primary: Number of Participants With Improvement in Pain — 11; 4 Participants
Phase 2 N=72 Nutrition and Body Composition in Acute Lymphoblastic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma · Vitamin D Deficiency
Primary: Change in Serum Vitamin D Level (Group A) — 5.5; -0.30; 1.0; 26.5 ng/ml
Phase 2 N=65 Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS) — 6.3; 4.5; 16.7; 0 Percentage of…
Phase 2 N=260 A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Systemic Lupus Erythematosus Responder Index (SRI)-4 Response at Week 48 — 44.2; 50.6; 51.7 Percentage of Participants — p=0.373
Phase 2 N=23 Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects
Depression
Primary: Montgomery-Asberg Depression Rating Scale — 27.9387; 26.5756; 16.5482; 20.9065 score on a scale
Phase 2 N=51 Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients
HIV Infections
Primary: To Compare the Phase 1 Viral Decay Rates Between LPV/r + RAL vs. EFV/TDF/FTC Treatment Combinations. — 0.47; 0.55 log(10)/day
Phase 2 N=30 Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
Primary Mitochondrial Disease
Primary: Distance Walked on the 6-minute Walk Test (6MWT) by Visit — 394.1; 378.2 meters
Phase 2 N=201 IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
Acute Pyelonephritis
Primary: Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) — 68; 15; 15; 16 Participants
Phase 2 N=42 Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Colon Adenocarcinoma · Rectal Adenocarcinoma · Recurrent Colon Carcinoma
Primary: To Examine the DLT — 200 mg
Phase 2 N=125 Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
Cataract
Primary: Aqueous Humour Concentration of Levofloxacin — 1.970; 2.151; 0 nmol/mL